Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study

NCT01769794 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2013-01-17

No results posted yet for this study

Summary

The study is aimed to evaluate the effectiveness and safety of Jinlianqingre Effervescent Tablets, a traditional Chinese medicine (TCM), in the treatment of Uncomplicated hand, foot, and mouth disease (HFMD).

Conditions

  • Hand, Foot and Mouth Disease

Interventions

DRUG

Western therapy

Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form

DRUG

JET

4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)

DRUG

Placebo(for JET)

placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)

Sponsors & Collaborators

  • Chengdu University of Traditional Chinese Medicine

    collaborator OTHER
  • Beijing Children's Hospital

    collaborator OTHER
  • Tianjin infectious disease hospital

    collaborator UNKNOWN
  • Tangshan infectious disease hospital

    collaborator UNKNOWN
  • The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

    collaborator OTHER
  • Tianjin Zhongshenghaitian Pharmaceutical Co. Ltd.

    collaborator UNKNOWN
  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Boyan Liu, chief physician · China Academy of Chinese Medical Sciences

  • Guoliang Zhang, chief · The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769794 on ClinicalTrials.gov